The forgotten class of drugs for multiple myeloma: HDAC inhibitors

Lancet Haematol. 2018 Dec;5(12):e604-e605. doi: 10.1016/S2352-3026(18)30194-7.

Authors

Noa Biran¹, David S Siegel², David H Vesole¹

Affiliations

¹ John Theurer Cancer Center at Hackensack University Medical Center, and Hackensack Meridian School of Medicine at Seton Hall University, Hackensack, NJ 07601, USA.
² John Theurer Cancer Center at Hackensack University Medical Center, and Hackensack Meridian School of Medicine at Seton Hall University, Hackensack, NJ 07601, USA. Electronic address: [email protected].

PMID: 30501864
DOI: 10.1016/S2352-3026(18)30194-7

No abstract available

MeSH terms

Histone Deacetylase Inhibitors / therapeutic use*
Humans
Multiple Myeloma / drug therapy*
Treatment Outcome

Substances

Histone Deacetylase Inhibitors